Peng Guo

Peng Guo

Auto-generated profile, based on publicly available information

Peng Guo

Nikon Imaging Center, Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Science Advances
Verified
Journal Article
Open access
RGRayyan M. Gorashi
Rayyan M. Gorashi
TBTalia Baddour
Talia Baddour
SCSarah J. Chittle
Sarah J. Chittle
NVNicole E. Félix Vélez
Nicole E. Félix Vélez
MWMichaela A. Wenning
Michaela A. Wenning
BABrian A. Aguado
Brian A. Aguado
Aortic valve stenosis (AVS) is a progressive disease, wherein males more often develop valve calcification relative to females that develop valve fibrosis. Valvular interstitial cells (VICs) aberrantly activate to myofibroblasts during AVS, driving the fibrotic valve phenotype in females. Myofibroblasts further differentiate into osteoblast-like cells and produce calcium nanoparticles, driving valve calcification in males. We hypothesized that the lysine demethylase UTY (ubiquitously transcribed tetratricopeptide repeat containing Y-linked) decreases methylation uniquely in male VICs responding to nanoscale extracellular matrix cues to promote an osteoblast-like cell phenotype. Here, we describe a hydrogel biomaterial cell culture platform to interrogate how nanoscale cues modulate sex-specific methylation states in VICs activating to myofibroblasts and osteoblast-like cells. We found that UTY modulates the osteoblast-like cell phenotype in response to nanoscale cues uniquely in male VICs. Overall, we reveal a previously unidentified role of UTY in the regulation of calcification processes in males during AVS progression.

6 June 2025 in Science Advances
Verified
Journal Article
Closed access
BVBrandon J. Vogt
Brandon J. Vogt
PWPeter Wang
Peter Wang
MCMegan Chavez
Megan Chavez
PGPeng Guo
Peng Guo
ECEdward Kai-Hua Chow
Edward Kai-Hua Chow
BABrian A. Aguado
Brian A. Aguado
Aortic valve stenosis (AVS) is a sexually dimorphic disease where aortic valve leaflets develop fibrosis and calcification, leading to heart failure if untreated. Sex differences in AVS progression depend on valvular interstitial cells (VICs) activating to myofibroblasts that drive aberrant extracellular matrix remodeling. To date, no treatment strategies have leveraged cellular sex differences to determine drug combinations that target VIC myofibroblast activation. Here, we harnessed IDentif.AI, an artificial intelligence (AI)–derived platform, to optimize sex-biased synergistic drug combinations that may prevent and reverse VIC myofibroblast activation on hydrogel biomaterials. The results reveal that sex-specific drug response models can be used to predict sex biases in drug efficacy and combinatorial interactions. This study provides a framework for developing AVS treatments through the integration of high-throughput hydrogel cell culture platforms and AI-driven drug optimization. Designing targeted AVS drug combinations may help accelerate AVS drug development and address health disparities in AVS treatment outcomes.